Differential modulation of Beta-adrenergic receptor signaling by trace amine-associated receptor 1 agonists. 2011

Gunnar Kleinau, and Juliane Pratzka, and Daniela Nürnberg, and Annette Grüters, and Dagmar Führer-Sakel, and Heiko Krude, and Josef Köhrle, and Torsten Schöneberg, and Heike Biebermann
Institute of Experimental Pediatric Endocrinology, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Trace amine-associated receptors (TAAR) are rhodopsin-like G-protein-coupled receptors (GPCR). TAAR are involved in modulation of neuronal, cardiac and vascular functions and they are potentially linked with neurological disorders like schizophrenia and Parkinson's disease. Subtype TAAR1, the best characterized TAAR so far, is promiscuous for a wide set of ligands and is activated by trace amines tyramine (TYR), phenylethylamine (PEA), octopamine (OA), but also by thyronamines, dopamine, and psycho-active drugs. Unfortunately, effects of trace amines on signaling of the two homologous β-adrenergic receptors 1 (ADRB1) and 2 (ADRB2) have not been clarified yet in detail. We, therefore, tested TAAR1 agonists TYR, PEA and OA regarding their effects on ADRB1/2 signaling by co-stimulation studies. Surprisingly, trace amines TYR and PEA are partial allosteric antagonists at ADRB1/2, whereas OA is a partial orthosteric ADRB2-antagonist and ADRB1-agonist. To specify molecular reasons for TAAR1 ligand promiscuity and for observed differences in signaling effects on particular aminergic receptors we compared TAAR, tyramine (TAR) octopamine (OAR), ADRB1/2 and dopamine receptors at the structural level. We found especially for TAAR1 that the remarkable ligand promiscuity is likely based on high amino acid similarity in the ligand-binding region compared with further aminergic receptors. On the other hand few TAAR specific properties in the ligand-binding site might determine differences in ligand-induced effects compared to ADRB1/2. Taken together, this study points to molecular details of TAAR1-ligand promiscuity and identified specific trace amines as allosteric or orthosteric ligands of particular β-adrenergic receptor subtypes.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D009655 Octopamine An alpha-adrenergic sympathomimetic amine, biosynthesized from tyramine in the CNS and platelets and also in invertebrate nervous systems. It is used to treat hypotension and as a cardiotonic. The natural D(-) form is more potent than the L(+) form in producing cardiovascular adrenergic responses. It is also a neurotransmitter in some invertebrates. Norsynephrine,p-Octopamine,para-Octopamine,4-Octopamine,Norsympatol,alpha-(Aminoethyl)-4-hydroxybenzenemethanol
D010627 Phenethylamines A group of compounds that are derivatives of beta- aminoethylbenzene which is structurally and pharmacologically related to amphetamine. (From Merck Index, 11th ed) Phenylethylamines
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000316 Adrenergic alpha-Agonists Drugs that selectively bind to and activate alpha adrenergic receptors. Adrenergic alpha-Receptor Agonists,alpha-Adrenergic Receptor Agonists,Adrenergic alpha-Agonist,Adrenergic alpha-Receptor Agonist,Receptor Agonists, Adrenergic alpha,Receptor Agonists, alpha-Adrenergic,alpha-Adrenergic Agonist,alpha-Adrenergic Agonists,alpha-Adrenergic Receptor Agonist,Adrenergic alpha Agonist,Adrenergic alpha Agonists,Adrenergic alpha Receptor Agonist,Adrenergic alpha Receptor Agonists,Agonist, Adrenergic alpha-Receptor,Agonist, alpha-Adrenergic,Agonist, alpha-Adrenergic Receptor,Agonists, Adrenergic alpha-Receptor,Agonists, alpha-Adrenergic,Agonists, alpha-Adrenergic Receptor,Receptor Agonist, alpha-Adrenergic,Receptor Agonists, alpha Adrenergic,alpha Adrenergic Agonist,alpha Adrenergic Agonists,alpha Adrenergic Receptor Agonist,alpha Adrenergic Receptor Agonists,alpha-Agonist, Adrenergic,alpha-Agonists, Adrenergic,alpha-Receptor Agonist, Adrenergic,alpha-Receptor Agonists, Adrenergic
D000494 Allosteric Regulation The modification of the reactivity of ENZYMES by the binding of effectors to sites (ALLOSTERIC SITES) on the enzymes other than the substrate BINDING SITES. Regulation, Allosteric,Allosteric Regulations,Regulations, Allosteric
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D014439 Tyramine An indirect sympathomimetic that occurs naturally in cheese and other foods. Tyramine does not directly activate adrenergic receptors, but it can serve as a substrate for adrenergic uptake systems and MONOAMINE OXIDASE to prolong the actions of adrenergic transmitters. It also provokes transmitter release from adrenergic terminals and may be a neurotransmitter in some invertebrate nervous systems. 4-(2-Aminoethyl)phenol,4-Hydroxyphenethylamine,p-Tyramine,para-Tyramine,4 Hydroxyphenethylamine
D015398 Signal Transduction The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway. Cell Signaling,Receptor-Mediated Signal Transduction,Signal Pathways,Receptor Mediated Signal Transduction,Signal Transduction Pathways,Signal Transduction Systems,Pathway, Signal,Pathway, Signal Transduction,Pathways, Signal,Pathways, Signal Transduction,Receptor-Mediated Signal Transductions,Signal Pathway,Signal Transduction Pathway,Signal Transduction System,Signal Transduction, Receptor-Mediated,Signal Transductions,Signal Transductions, Receptor-Mediated,System, Signal Transduction,Systems, Signal Transduction,Transduction, Signal,Transductions, Signal

Related Publications

Gunnar Kleinau, and Juliane Pratzka, and Daniela Nürnberg, and Annette Grüters, and Dagmar Führer-Sakel, and Heiko Krude, and Josef Köhrle, and Torsten Schöneberg, and Heike Biebermann
November 2017, Biological psychiatry,
Gunnar Kleinau, and Juliane Pratzka, and Daniela Nürnberg, and Annette Grüters, and Dagmar Führer-Sakel, and Heiko Krude, and Josef Köhrle, and Torsten Schöneberg, and Heike Biebermann
January 2018, Frontiers in pharmacology,
Gunnar Kleinau, and Juliane Pratzka, and Daniela Nürnberg, and Annette Grüters, and Dagmar Führer-Sakel, and Heiko Krude, and Josef Köhrle, and Torsten Schöneberg, and Heike Biebermann
December 2012, Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology,
Gunnar Kleinau, and Juliane Pratzka, and Daniela Nürnberg, and Annette Grüters, and Dagmar Führer-Sakel, and Heiko Krude, and Josef Köhrle, and Torsten Schöneberg, and Heike Biebermann
September 2025, Molecular pharmacology,
Gunnar Kleinau, and Juliane Pratzka, and Daniela Nürnberg, and Annette Grüters, and Dagmar Führer-Sakel, and Heiko Krude, and Josef Köhrle, and Torsten Schöneberg, and Heike Biebermann
February 2024, Sheng li xue bao : [Acta physiologica Sinica],
Gunnar Kleinau, and Juliane Pratzka, and Daniela Nürnberg, and Annette Grüters, and Dagmar Führer-Sakel, and Heiko Krude, and Josef Köhrle, and Torsten Schöneberg, and Heike Biebermann
January 2016, Molecular metabolism,
Gunnar Kleinau, and Juliane Pratzka, and Daniela Nürnberg, and Annette Grüters, and Dagmar Führer-Sakel, and Heiko Krude, and Josef Köhrle, and Torsten Schöneberg, and Heike Biebermann
June 2005, The Journal of pharmacology and experimental therapeutics,
Gunnar Kleinau, and Juliane Pratzka, and Daniela Nürnberg, and Annette Grüters, and Dagmar Führer-Sakel, and Heiko Krude, and Josef Köhrle, and Torsten Schöneberg, and Heike Biebermann
August 2024, Science advances,
Gunnar Kleinau, and Juliane Pratzka, and Daniela Nürnberg, and Annette Grüters, and Dagmar Führer-Sakel, and Heiko Krude, and Josef Köhrle, and Torsten Schöneberg, and Heike Biebermann
October 2015, The Journal of neuroscience : the official journal of the Society for Neuroscience,
Gunnar Kleinau, and Juliane Pratzka, and Daniela Nürnberg, and Annette Grüters, and Dagmar Führer-Sakel, and Heiko Krude, and Josef Köhrle, and Torsten Schöneberg, and Heike Biebermann
March 2008, The Journal of pharmacology and experimental therapeutics,
Copied contents to your clipboard!